Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
NCT00843882Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2009
- Primary completion
- Jul 2019
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
A Phase 3 trial of epoetin alfa in myelodysplastic syndrome (MDS), anemia, chronic myelomonocytic leukemia (CMML), sponsored by National Cancer Institute. Started Apr 2009; status: active, not recruiting.
02
Drugs
epoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)anemiachronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00843882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00843882.